Frank Herringer Nominated for Amgen Board of Directors| Amgen

Frank Herringer Nominated for Amgen Board of Directors

THOUSAND OAKS, Calif., March 10 -- Amgen Inc. (Nasdaq: AMGN), the world's largest biotechnology company, today announced that Frank C. Herringer has agreed to stand as one of the company's nominees to the board of directors at its upcoming Annual Meeting of Stockholders on May 13, 2004. Herringer is Chairman of the Board of Transamerica Corporation, a leading financial services company.

Frank Herringer has a long and successful history with Transamerica, joining the company in 1979 as vice president. He became president in 1986, added the title of Chief Executive Officer in 1991 and held the positions of Chairman of the Board and Chief Executive Officer from 1995 to 1999, when Transamerica was acquired by Aegon, N.V. From 1999 to 2000, Herringer served on the Executive Board of Aegon N.V. and was Chairman of the Board of Aegon U.S.A

"We are excited about Frank Herringer's nomination and look forward to his pending election by our shareholders in May," said Kevin Sharer, Amgen's chairman and chief executive officer. "With his business and financial acumen, Frank would be a wonderful addition to the board, adding valuable insight as we continue to expand our leadership role in the biotech and pharmaceutical industries."

Herringer also serves as a director for other companies including, AT&T Corp., The Charles Schwab Corporation and Unocal Corporation.

Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.

Amgen, Thousand Oaks
Mary Klem, (805) 447-4587 (media)
Cary Rosansky, (805) 447-1060 (investors)